Search
Powered By HealthLine
Health Tools
 Arthritis Questions and Answers
 Arthritis Symptom Checker
 Arthritis Drug Information
 Preventing Arthritis
 Arthritis Treatment
Featured Conditions
 Osteoarthritis
 Chronic Pain
 Rheumatoid Arthritis
 Diet & Exercise
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & PrecautionsAdditional Info
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Cefzil

[Cefprozil]


Patient Info
Information for Patients

Phenylketonurics:

CEFZIL (cefprozil) for oral suspension contains phenylalanine 28 mg per 5 mL (1 teaspoonful) constituted suspension for both the 125 mg/ 5 mL and 250 mg/ 5 mL dosage forms.

Text Continues Below



Patients should be counseled that antibacterial drugs including CEFZIL should only be used to treat bacterial infections. They do not treat viral infections (e. g., the common cold).

When CEFZIL is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.

Skipping doses or not completing the full course of therapy may

(1) decrease the effectiveness of the immediate treatment and

(2) increase the likelihood that bacteria will develop resistance and will not be treatable by CEFZIL or other antibacterial drugs in the future.









HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire